Angiotensin Ii Acetate Patent Expiration
Angiotensin Ii Acetate is used for increasing blood pressure and treating shock, especially in patients unresponsive to other vasopressors. It was first introduced by La Jolla Pharma Llc
Angiotensin Ii Acetate Patents
Given below is the list of patents protecting Angiotensin Ii Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Giapreza | US11219662 | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II | Jan 06, 2037 | La Jolla Pharma |
| Giapreza | US10028995 | Angiotensin II alone or in combination for the treatment of hypotension | Dec 18, 2034 | La Jolla Pharma |
| Giapreza | US10493124 | Angiotensin II alone or in combination for the treatment of hypotension | Dec 18, 2034 | La Jolla Pharma |
| Giapreza | US11096983 | Angiotensin II alone or in combination for the treatment of hypotension | Dec 18, 2034 | La Jolla Pharma |
| Giapreza | US11559559 | Angiotensin II alone or in combination for the treatment of hypotension | Dec 18, 2034 | La Jolla Pharma |
| Giapreza | US9220745 | Angiotensin II alone or in combination for the treatment of hypotension | Dec 18, 2034 | La Jolla Pharma |
| Giapreza | US9572856 | Method of treating low blood pressure | Jul 18, 2031 | La Jolla Pharma |
| Giapreza | US9572856 | Method of treating low blood pressure | Nov 20, 2030 | La Jolla Pharma |
| Giapreza | US10335451 | Method of treating low blood pressure | Dec 16, 2029 | La Jolla Pharma |
| Giapreza | US10500247 | Method of treating low blood pressure | Dec 16, 2029 | La Jolla Pharma |
| Giapreza | US10548943 | Method of treating low blood pressure | Dec 16, 2029 | La Jolla Pharma |
| Giapreza | US9867863 | Method of treating low blood pressure | Dec 16, 2029 | La Jolla Pharma |
Angiotensin Ii Acetate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List